Education
About Us
Working with TipRanks
Follow Us
GeoVax Labs (GOVX)
NASDAQ:GOVX
Top Page
GeoVax Labs
(NASDAQ:GOVX)
Select Model
Select Model
Rating:34Underperform
Price Target:―
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
Positive Factors
Vaccine Development Portfolio
GeoVax's robust vaccine development portfolio positions it to address unmet healthcare needs, potentially leading to expedited registration and market entry.
Strategic Partnerships
Strategic partnerships enhance GeoVax's global development and commercialization efforts, potentially increasing market reach and funding opportunities.
Cash Position
A strong cash position provides GeoVax with a buffer to manage operational expenses and invest in R&D, supporting long-term sustainability despite current challenges.
Negative Factors
BARDA Contract Termination
The BARDA contract termination poses a strategic setback, potentially affecting financial support and delaying vaccine development timelines.
Negative Cash Flow
Persistent negative cash flow highlights cash management challenges, necessitating reliance on external financing and raising concerns about financial sustainability.
Increased Expenses
Rising R&D and administrative expenses could strain financial resources, impacting profitability and necessitating careful cost management to ensure long-term viability.
GeoVax Labs (GOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.38M
Dividend YieldN/A
Average Volume (3M)669.25K
Price to Earnings (P/E)―
Beta (1Y)2.89
Revenue Growth1943.07%
EPS Growth80.97%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding25,359,592
10 Day Avg. Volume613,495
30 Day Avg. Volume669,253
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.54
Price to Sales (P/S)3.24
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$12.00Price Target Upside1746.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
GeoVax Labs Business Overview & Revenue Model
Company DescriptionGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
How the Company Makes MoneyGeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.
GeoVax Labs Earnings Call Summary
Earnings Call Date:Aug 06, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in revenue growth, regulatory advancements for GEO-MVA, and successful fundraising efforts. However, challenges such as the termination of the BARDA contract, increased expenses, and delays in clinical trials were also noted.Q2-2025 Updates
Positive Updates
Revenue Increase
GeoVax reported revenues of $2.5 million for the first half of 2025, a significant increase from $301,000 in the same period in 2024, primarily due to the BARDA project NextGen contract.
EMA Guidance for GEO-MVA
GeoVax received guidance from the European Medicines Agency (EMA) for an expedited development path for its GEO-MVA vaccine, allowing the company to bypass Phase I and Phase II clinical trials.
Advancements in Vaccine Manufacturing
The advanced MVA manufacturing process is expected to provide a game-changing advantage in the production of MVA-based vaccines and therapies.
Expansion of Clinical Trials
GeoVax has expanded its clinical trials for GEO-CMO4S1, including a new site at the City of Hope facility for CLL patients.
Successful Fundraising
GeoVax concluded a follow-on public offering in July, raising almost $6 million in net proceeds, boosting its cash reserves.
Negative Updates
BARDA Contract Termination
The BARDA project NextGen contract was terminated as part of the government's efficiency program, impacting future revenue streams.
Increased Expenses
Research and development expenses increased by $1.4 million or 16%, and general and administrative expenses rose by $686,000 or 27%.
Net Loss
GeoVax reported a net loss of $10.7 million for the first half of 2025, compared to a net loss of $10.9 million in the same period in 2024.
Delays in Clinical Trials
The GEO-MVA and Gedeptin trials are not expected to start until the second half of 2026, indicating potential delays in product development.
Company Guidance
During the GeoVax Second Quarter 2025 Corporate Update Call, significant guidance was provided regarding the company's strategic path forward. The European Medicines Agency (EMA) granted an expedited development path for the GEO-MVA vaccine, allowing it to skip Phase I and II trials and proceed directly to a Phase III immunobridging trial, potentially accelerating its market authorization and revenue generation. The company also reported progress on its GEO-CMO4S1 COVID-19 vaccine, specifically targeting over 40 million immunocompromised adults in the U.S. and 400 million worldwide, with ongoing Phase II trials focusing on patients with blood cancers. Financially, GeoVax reported a net loss of $10.7 million for the first half of 2025, primarily due to increased R&D expenses of $10 million, driven by the BARDA contract and the Gedeptin and GEO-MVA programs. The company ended the second quarter with $3.1 million in cash but raised an additional $6 million in a follow-on public offering in July.GeoVax Labs Financial Statement Overview
Summary
GeoVax Labs faces significant financial challenges with no revenue growth and continuous net losses, reflecting operational and market difficulties. The company's strong cash position offsets some risks, but negative cash flows and reliance on financing indicate potential financial instability.Income Statement
GeoVax Labs has consistently reported zero or negligible revenue, indicating a significant challenge in generating sales. The company has experienced persistent net losses with negative EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to its revenue base.10
Very Negative
Balance Sheet
The balance sheet shows a relatively strong cash position with no debt, which is a positive sign of financial prudence. However, the equity ratio is weak due to a low level of total assets and historical negative equity, posing risks to financial stability and growth potential.25
Negative
Cash Flow
GeoVax Labs exhibits negative operating and free cash flow, indicating potential cash management issues. The company relies heavily on financing activities to support its operations, raising concerns about sustainability and the need for continued external funding.15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.14M | 3.95M | 0.00 | 81.00K | 385.00K | 1.82M |
| Gross Profit | 6.12M | 3.86M | -20.72M | 24.72K | -15.17M | -621.46K |
| EBITDA | -24.82M | -24.88M | -26.67M | -13.97M | -18.53M | -2.79M |
| Net Income | -24.81M | -24.99M | -25.97M | -14.01M | -18.53M | -2.96M |
Balance Sheet | ||||||
| Total Assets | 5.35M | 8.16M | 9.28M | 31.35M | 11.80M | 10.39M |
| Cash, Cash Equivalents and Short-Term Investments | 3.09M | 5.51M | 6.45M | 27.61M | 11.42M | 9.88M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 198.06K |
| Total Liabilities | 2.53M | 3.11M | 3.52M | 4.75M | 7.43M | 825.00K |
| Stockholders Equity | 2.82M | 5.05M | 5.76M | 26.60M | 4.36M | 9.57M |
Cash Flow | ||||||
| Free Cash Flow | -27.37M | -24.70M | -25.22M | -19.16M | -11.24M | -2.91M |
| Operating Cash Flow | -27.35M | -24.68M | -25.17M | -19.03M | -11.20M | -2.75M |
| Investing Cash Flow | -48.27K | -20.65K | -48.95K | -134.26K | -47.72K | -156.79K |
| Financing Cash Flow | 28.93M | 23.75M | 4.06M | 35.35M | 12.78M | 12.51M |
GeoVax Labs Technical Analysis
Negative
0.65
Price Trends
0.73
Negative
0.82
Negative
1.25
Negative
Market Momentum
-0.02
Positive
38.59
Neutral
24.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.69, below the 50-day MA of 0.73, and below the 200-day MA of 1.25, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.59 is Neutral, neither overbought nor oversold. The STOCH value of 24.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | 15.02M | 0.77 | 72.91% | ― | -82.24% | ― | |
44 Neutral | 24.35M | -0.11 | ― | ― | ― | 60.64% | |
43 Neutral | 74.39M | -17.12 | ― | ― | 186.84% | 89.16% | |
42 Neutral | 12.77M | -0.67 | ― | ― | ― | 85.26% | |
40 Underperform | 11.10M | -0.41 | ― | ― | ― | 9.63% | |
34 Underperform | $16.38M | ― | -9690.24% | ― | 1943.07% | 80.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
GOVX
GeoVax Labs
0.65
-1.76
-73.03%
PHIO
Phio Pharmaceuticals
2.23
-1.22
-35.36%
MBRX
Moleculin Biotech
0.49
-2.35
-82.75%
ABVC
ABVC BioPharma
3.16
2.48
364.71%
ADXN
Addex Therapeutics
8.94
-0.83
-8.50%
SNSE
Sensei Biotherapeutics
8.80
-3.16
-26.42%
GeoVax Labs Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
Negative
Apr 14, 2025
On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.
To see Spark’s full report on GOVX stock, click here.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.